[go: up one dir, main page]

NI201400104A - Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento - Google Patents

Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento

Info

Publication number
NI201400104A
NI201400104A NI201400104A NI201400104A NI201400104A NI 201400104 A NI201400104 A NI 201400104A NI 201400104 A NI201400104 A NI 201400104A NI 201400104 A NI201400104 A NI 201400104A NI 201400104 A NI201400104 A NI 201400104A
Authority
NI
Nicaragua
Prior art keywords
treatment
esketamine
resistant
depression
refractory
Prior art date
Application number
NI201400104A
Other languages
English (en)
Inventor
Singh Jaskaran
Ivo Caers Lodewijk
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201400104A publication Critical patent/NI201400104A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a métodos para el tratamiento de la depresión refractaria al tratamiento o depresión resistente al tratamiento; los métodos comprenden administrar a un paciente que lo necesita una cantidad terapéuticamente eficaz de esketamina como monoterapia o como terapia de combinación con al menos un antidepresivo.
NI201400104A 2012-03-12 2014-09-10 Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento NI201400104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261609641P 2012-03-12 2012-03-12
US201261610058P 2012-03-13 2012-03-13

Publications (1)

Publication Number Publication Date
NI201400104A true NI201400104A (es) 2016-11-30

Family

ID=47913632

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201400104A NI201400104A (es) 2012-03-12 2014-09-10 Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento

Country Status (14)

Country Link
US (2) US20130236573A1 (es)
KR (1) KR20140136982A (es)
CN (1) CN104519878A (es)
CL (1) CL2014002406A1 (es)
CO (1) CO7071129A2 (es)
CR (1) CR20140410A (es)
GT (1) GT201400191A (es)
HK (1) HK1209323A1 (es)
MX (1) MX2014010939A (es)
NI (1) NI201400104A (es)
PE (1) PE20141906A1 (es)
PH (1) PH12014501997A1 (es)
SG (1) SG11201405530SA (es)
WO (1) WO2013138322A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
BR112015022972B1 (pt) 2013-03-15 2023-02-14 Janssen Pharmaceutica Nv Composição farmacêutica de cloridrato de s-cetamina e formas de dosagem da mesma
MX370506B (es) 2013-04-12 2019-12-16 Icahn School Med Mount Sinai Método para tratar trastorno de estrés post-traumático.
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
CA2936809A1 (en) * 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
HUE051264T2 (hu) 2014-04-17 2021-03-01 Develco Pharma Schweiz Ag Ketamin orális dózisformája
KR20170013890A (ko) * 2014-05-06 2017-02-07 노쓰웨스턴유니버시티 Nmdar 조절 화합물의 조합물
JP6545788B2 (ja) * 2014-08-13 2019-07-17 ヤンセン ファーマシューティカ エヌ．ベー． うつ病の治療方法
CN107208133A (zh) 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
WO2016094358A1 (en) 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20180015054A1 (en) * 2014-12-31 2018-01-18 Icahn School Of Medicine At Mount Sinai Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
WO2016172672A1 (en) * 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
HK1248578A1 (zh) 2015-06-27 2018-10-19 Shenox Pharmaceuticals, Llc 氯胺酮透皮递送系统
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
US11110070B2 (en) 2015-11-17 2021-09-07 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
JPWO2018079693A1 (ja) * 2016-10-27 2019-10-31 国立大学法人千葉大学 （ｓ）−ノルケタミンおよびその塩の医薬品としての応用
EP3641742A2 (en) * 2017-06-23 2020-04-29 Develco Pharma Schweiz AG Hydroxynorketamine for the use in the treatment of depression
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
CN107823195A (zh) * 2017-11-24 2018-03-23 无锡市精神卫生中心 R‑氯胺酮在抑郁症急性期治疗中的应用
CN112423789A (zh) * 2017-12-22 2021-02-26 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
EP3505157B1 (en) * 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
US11426367B2 (en) 2018-05-04 2022-08-30 Perception Neuroscience, Inc. Methods of treating substance abuse
EP3813807A1 (en) 2018-06-27 2021-05-05 Clexio Biosciences Ltd. Method of treating major depressive disorder
WO2020027344A1 (en) * 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Ch24h inhibitors for mdd use
PL3628313T3 (pl) 2018-09-28 2025-06-23 Novohale Therapeutics, Llc Kompozycja ketaminy do zastosowania w sposobie leczenia depresji przez podawanie dopłucne
CA3113198A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2020168337A1 (en) * 2019-02-17 2020-08-20 Magid Abraham Compositions and methods for treatment of depression and other disorders
JP2022524008A (ja) 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
US20220062200A1 (en) * 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN113905777B (zh) 2019-05-31 2025-06-20 赛隆制药股份公司 用于电子监督胃肠外施用药物组合物的吸入器
KR20220012922A (ko) 2019-05-31 2022-02-04 셀론 파르마 에스.에이. 약학적 조성물의 전자적으로 관리된 투여
EP4021432A4 (en) * 2019-08-28 2023-08-16 Janssen Pharmaceuticals, Inc. ESKETAMIN FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
CA3153856A1 (en) * 2019-09-13 2021-03-18 Janssen Pharmaceuticals, Inc. Intranasal administration of esketamine
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
CN115768519A (zh) * 2020-05-28 2023-03-07 詹森药业有限公司 治疗抑郁症的方法
JP2023538901A (ja) 2020-08-18 2023-09-12 オークウッド ラボラトリーズ，エル．エル．シー． ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
CN114681407A (zh) * 2020-12-30 2022-07-01 北京万全德众医药生物技术有限公司 一种盐酸艾司氯胺酮颗粒剂
JP2025087929A (ja) * 2022-02-22 2025-06-11 国立大学法人京都大学 うつ病および／またはうつ状態の治療および／または予防用医薬
WO2025057111A1 (en) * 2023-09-12 2025-03-20 Clexio Biosciences Ltd. Esketamine or a pharmaceutical salt thereof for use in a method of treating major depressive disorder
CN120919140A (zh) * 2025-09-09 2025-11-11 徐州百瑞麻醉科技研究院有限公司 一种艾司氯胺酮与米氮平协同的抗抑郁药物组合物及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176242B1 (en) * 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
MXPA05000294A (es) * 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
BRPI0711872A2 (pt) * 2006-05-22 2011-12-06 Vanda Pharmaceuticals Inc tratamento para distúrbios depressivos
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
ES2560676T3 (es) * 2010-06-15 2016-02-22 Grünenthal GmbH Combinación farmacéutica para el tratamiento del dolor

Also Published As

Publication number Publication date
KR20140136982A (ko) 2014-12-01
MX2014010939A (es) 2014-11-13
HK1209323A1 (en) 2016-04-01
CR20140410A (es) 2014-11-17
US20130236573A1 (en) 2013-09-12
PH12014501997A1 (en) 2014-11-24
CO7071129A2 (es) 2014-09-30
CL2014002406A1 (es) 2015-01-09
CN104519878A (zh) 2015-04-15
WO2013138322A1 (en) 2013-09-19
SG11201405530SA (en) 2014-11-27
PE20141906A1 (es) 2014-12-05
GT201400191A (es) 2017-07-03
US20140093592A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
MX391175B (es) Macrociclos peptidomimeticos.
MX2015006234A (es) Uso de akkermansia para tratar trastornos metabolicos.
DOP2014000170A (es) Compuestos de imidazopirrolidinona
MX393610B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
MX2014012381A (es) Terapia de combinacion para tratar cancer.
MX356052B (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
BR112015026325A2 (pt) dosagem oral de compostos glp-1
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
NI201200030A (es) Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas.
CL2014001993A1 (es) Uso de melatonina para el tratamiento de trastornos del ritmo circadiano
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
ECSP21015491A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
BR112015025719A2 (pt) terapia contra o câncer
BR112014011223A8 (pt) Método de tratar uma doença proliferativa
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
ES2569743R1 (es) Uso de la buprenorfina en la fabricación de un medicamento para tratar los efectos secundarios inducidos por opioides